Showing 7121-7130 of 8649 results for "".
- Qlaris Bio’s Novel IOP-Lowering Product, QLS‑111, is Dosed in Phase 2 Trialshttps://modernod.com/news/qlaris-bios-novel-iop-lowering-product-qls111-is-dosed-in-phase-2-trials/2482195/Qlaris Bio announced the initiation and dosing of two separate US phase 2 masked, randomized clinical trials investigating QLS‑111 in patients with ocular hypertension and glaucoma. “The start of these phase 2 trials represents a key milestone in our goal of bringing QLS‑111
- Iveric Bio Receives Permanent J-code for GA Treatment Izervayhttps://modernod.com/news/iveric-bio-receives-permanent-j-code-for-ga-treatment-izervay/2482181/Iveric Bio, a subsidiary of Astellas, announced that CMS has assigned a unique, permanent Healthcare Common Procedure Coding System (HCPS) J-code for Izervay (avacincaptad pegol intravitreal solution) for the treatment of geographic atrophy (GA) secondary to age-related macula
- BlueRock Therapeutics and Foundation Fighting Blindness Partner for IRD Studyhttps://modernod.com/news/bluerock-therapeutics-and-foundation-fighting-blindness-partner-for-ird-study/2482178/BlueRock Therapeutics LP, a clinical stage cell therapy company and subsidiary of Bayer, and Foundation Fighting Blindness announced a collaboration to add a new cohort to the Foundation’s 'Uni-Rare natural history study' of people living with inherited retinal diseases (I
- Lenz Therapeutics Completes Merger with Graphite Bio; Debuts on Nasdaqhttps://modernod.com/news/lenz-therapeutics-completes-merger-with-graphite-bio-to-debut-on-nasdaq/2482177/Lenz Therapeutics announced the completion of its previously announced merger with Graphite Bio. The new combined company will operate under the name Lenz Therapeutics and will commence trading on Nasdaq under the ticker symbol “LENZ” on March 22, 2024. &ldquo
- Mice Sent to Space on SpaceX Rocket as Part of Oculogenex Gene Therapy Studyhttps://modernod.com/news/gene-therapy-company-oculogenex-set-to-launch-on-spacex-crs-30-today/2482175/Today’s scheduled launch of NASA’s SpaceX CRS-30 mission will carry more than 40 science payloads to the International Space Station for a new round of microgravity research. SpaceX CRS-30 is scheduled to launch today at 4:55 ET. The mission will include Oculogene
- Staar Surgical Celebrates Three Million Implantable Collamer Lenseshttps://modernod.com/news/staar-surgical-celebrates-three-million-implantable-collamer-lenses/2482170/Staar Surgical announced that more than 3 million Implantable Collamer Lens (ICLs) have been sold globally.[1] “We extend our sincere gratitude to the surgeons and clinicians with whom we partner and to their patients who have chosen our ICLs for their vision correction
- NewSight Reality Unveils Transparent Optical Module (TOM) 2.0 at Vision Expo East 2024https://modernod.com/news/newsight-reality-unveils-transparent-optical-module-tom-20-at-vision-expo-east-2024/2482167/NewSight Reality (NSR), a provider of Augmented Reality (AR) technologies, announced the next generation of its Transparent Optical Module (TOM) 2.0 at the Vision Expo East meeting. Highlights of the new technology include a patented stray light shielding solution, active micro-len
- Virtual Vision Health Unveils New Features for Virtual Eye Prohttps://modernod.com/news/virtual-vision-health-unveils-new-features-for-virtual-eye-pro/2482166/Virtual Vision Health has announced it will showcase new testing features on its Virtual Eye Pro at Vision Expo East and ASCRS 2024. Developed and validated at Bascom Palmer Eye Institute, the virtual reality visual field headset is designed to increase practice efficienc
- Neurolens Restructures Leadership Teamhttps://modernod.com/news/neurolens-restructures-leadership-team/2482165/Neurolens announced a strategic leadership restructure, which includes Davis Corley, co-founder, returning as CEO. Other leadership hires: Gregory Boisse, SVP of Operations Nathan Schomas, SVP of Digital Innovation
- OcuTerra Fails Phase 2 DR:EAM Trial Evaluating Nesvategrast for Diabetic Retinopathyhttps://modernod.com/news/ocuterra-fails-phase-2-dream-trial-evaluating-nesvategrast-for-diabetic-retinopathy/2482163/OcuTerra Therapeutics announced topline results from its phase 2 DR:EAM (Diabetic Retinopathy: Early Active Management) clinical trial of nesvategrast (OTT166), a novel, selective RGD integrin inhibitor developed as an eye drop. The clinical trial did not meet its primary or key secondary ef